- Home
- Search
- Tools
- Saved
- 0Notifications
- CME
- Help & Feedback
- About epocrates
- Business Solutions
Highlights & Basics
- Oral mucositis (OM) is an acute inflammation of the oral mucosa following systemic cancer therapy, particularly chemotherapy, and/or radiation therapy. Diagnosis is typically based on clinical history and physical exam.
- Clinical presentation varies from erythema to patchy or confluent ulceration with a superficial pseudomembranous membrane or, rarely, overt necrosis.
- Lesions are often very painful. Treatment is symptomatic and includes oral hygiene and pain control.
- If severe, may warrant an undesirable dose-reduction and/or a break in cancer therapy.
- Preventive measures in high-risk patients include palifermin, intraoral low-level laser therapy, and use of oral cryotherapy during chemotherapy infusion.
Quick Reference
History & Exam
Key Factors
Other Factors
Diagnostics Tests
Treatment Options
Definition
Epidemiology
Etiology
Pathophysiology
Images
Mucositis: buccal mucosa
Mucositis: dorsolateral tongue
Candidal pseudomembranes on the palate, third week of radiation therapy for the management of nasopharyngeal carcinoma. It was diagnosed during the regular, weekly examination. Patient reported xerostomia and mild discomfort
Oral herpes virus infection presenting as painful ulcers covered by pseudomembranes on the right side of the dorsum of the tongue. Diagnosed during the third week of radiation therapy for the management of the maxillary sinus carcinoma. Responded to acyclovir
Clinical criteria for differential diagnosis of oral mucositis from candidiasis and herpes simplex virus infection
Citations
Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-31.[Abstract][Full Text]
Peterson DE, Boers-Doets CB, Bensadoun RJ, et al; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v139-51.[Full Text]
1. Sroussi HY, Epstein JB, Bensadoun RJ, et al. Common oral complications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease, and osteoradionecrosis. Cancer Med. 2017 Dec;6(12):2918-31.[Abstract][Full Text]
2. Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent Clin North Am. 2014 Apr;58(2):341-9.[Abstract]
3. Elting LS, Cooksley CD, Chambers MS, et al. Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1110-20.[Abstract]
4. Jones JA, Avritscher EB, Cooksley CD, et al. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006 Jun;14(6):505-15.[Abstract]
5. Vera-Llonch M, Oster G, Ford CM, et al. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. Support Care Cancer. 2007 May;15(5):491-6.[Abstract]
6. Vera-Llonch M, Oster G, Hagiwara M, et al. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006 Jan 15;106(2):329-36.[Abstract][Full Text]
7. Vagliano L, Feraut C, Gobetto G, et al. Incidence and severity of oral mucositis in patients undergoing haematopoietic SCT-results of a multicentre study. Bone Marrow Transplant. 2011 May;46(5):727-32.[Abstract]
8. Chaudhry HM, Bruce AJ, Wolf RC, et al. The incidence and severity of oral mucositis among allogeneic hematopoietic stem cell transplantation patients: a systematic review. Biol Blood Marrow Transplant. 2016 Apr;22(4):605-16.[Abstract][Full Text]
9. Liu M, An R, Wu Z, et al. The trajectory of oral mucositis in head and neck cancer patients undergoing radiotherapy and its influencing factors. Ear Nose Throat J. 2024 Feb 9:1455613241228211.[Abstract][Full Text]
10. Iovoli AJ, Turecki L, Qiu ML, et al. Severe oral mucositis after intensity-modulated radiation therapy for head and neck cancer. JAMA Netw Open. 2023 Oct 2;6(10):e2337265.[Abstract][Full Text]
11. Elad S, Yarom N, Zadik Y, et al. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022 Jan;72(1):57-77.[Abstract][Full Text]
12. Elting LS, Keefe DM, Sonis ST, et al. Patient-reported measurements of oral mucositis in head and neck cancer patients treated with radiotherapy with or without chemotherapy: demonstration of increased frequency, severity, resistance to palliation, and impact on quality of life. Cancer. 2008 Nov 15;113(10):2704-13.[Abstract]
13. Wardill HR, Sonis ST, Blijlevens NMA, et al. Prediction of mucositis risk secondary to cancer therapy: a systematic review of current evidence and call to action. Support Care Cancer. 2020 Nov;28(11):5059-73.[Abstract]
14. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. Transl Lung Cancer Res. 2015 Oct;4(5):560-75.[Abstract][Full Text]
15. Villa A, Kuten-Shorrer M. Pathogenesis of oral toxicities associated with targeted therapy and immunotherapy. Int J Mol Sci. 2023 May 3;24(9):8188.[Abstract][Full Text]
16. Al-Dasooqi N, Sonis ST, Bowen JM, et al. Emerging evidence on the pathobiology of mucositis. Support Care Cancer. 2013 Nov;21(11):3233-41.[Abstract]
17. Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010 Oct;16(7):597-600.[Abstract]
18. Mougeot JC, Stevens CB, Morton DS, et al. Oral Microbiome and Cancer Therapy-Induced Oral Mucositis. J Natl Cancer Inst Monogr. 2019 Aug 1;2019(53):lgz002.[Abstract]
19. Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019 Oct;27(10):4023-33.[Abstract]
20. Nakagaki M, Kennedy GA, Gavin NC, et al. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation. Support Care Cancer. 2022 Nov;30(11):9141-9.[Abstract][Full Text]
21. Van Kuilenburg AB, Meinsma R, Zoetekouw L, et al. High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics. 2002 Oct;12(7):555-8.[Abstract]
22. Elad S, Cheng KKF, Lalla RV, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-31.[Abstract][Full Text]
23. Peterson DE, Ohrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. Support Care Cancer. 2013 Jan;21(1):327-32.[Abstract]
24. Peterson DE, Boers-Doets CB, Bensadoun RJ, et al; ESMO Guidelines Committee. Management of oral and gastrointestinal mucosal injury: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015 Sep;26(suppl 5):v139-51.[Full Text]
25. Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev. 2015 Dec 23;(12):CD011552.[Abstract][Full Text]
26. de Lima Martins JO, Carlos ACAM, Costa GAJ, et al. Oral hygiene protocols reduce the severity and incidence of oral mucositis during antineoplastic treatment: a systematic review and meta-analysis of randomized and non-randomized clinical trials. Support Care Cancer. 2023 Jul 21;31(8):480.[Abstract]
27. McGuire DB, Fulton JS, Park J, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients. Support Care Cancer. 2013 Nov;21(11):3165-77.[Abstract]
28. Tso TV, Hurwitz M, Margalit DN, et al. Radiation dose enhancement associated with contemporary dental materials. J Prosthet Dent. 2019 Apr;121(4):703-7.[Abstract]
29. Migliorati C, Hewson I, Lalla RV, et al. Systematic review of laser and other light therapy for the management of oral mucositis in cancer patients. Support Care Cancer. 2013 Jan;21(1):333-41.[Abstract]
30. Lopes NN, Plapler H, Chavantes MC, et al. Cyclooxygenase-2 and vascular endothelial growth factor expression in 5-fluorouracil-induced oral mucositis in hamsters: evaluation of two low-intensity laser protocols. Support Care Cancer. 2009 Nov;17(11):1409-15.[Abstract]
31. Lopes NN, Plapler H, Lalla RV, et al. Effects of low-level laser therapy on collagen expression and neutrophil infiltrate in 5-fluorouracil-induced oral mucositis in hamsters. Lasers Surg Med. 2010 Aug;42(6):546-52.[Abstract]
32. Nicolatou-Galitis O, Sarri T, Bowen J, et al. Systematic review of anti-inflammatory agents for the management of oral mucositis in cancer patients. Support Care Cancer. 2013 Nov;21(11):3179-89.[Abstract]
33. UK Oral Management in Cancer Care Group. Oral Care guidance and support in cancer and palliative care. Jun 2019 [internet publication].[Full Text]
34. Sougiannis AT, VanderVeen BN, Davis JM, et al. Understanding chemotherapy-induced intestinal mucositis and strategies to improve gut resilience. Am J Physiol Gastrointest Liver Physiol. 2021 May 1;320(5):G712-9.[Abstract][Full Text]
35. Berger K, Schopohl D, Bollig A, et al. Burden of oral mucositis: a systematic review and implications for future research. Oncol Res Treat. 2018;41(6):399-405.[Abstract][Full Text]
36. Lee SC, Wang TJ, Chu PY. Predictors of weight loss during and after radiotherapy in patients with head and neck cancer: a longitudinal study. Eur J Oncol Nurs. 2019 Apr;39:98-104.[Abstract]
37. World Health Organization. WHO handbook for reporting results of cancer treatment. 1979 [internet publication].[Full Text]
38. National Cancer Institute. Common terminology criteria for adverse events (CTCAE): version 5.0. Nov 2017 [internet publication].[Full Text]
39. Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010 Aug;18(8):985-92.[Abstract][Full Text]
40. Soysa NS, Samaranayake LP, Ellopola AN. Cytotoxic drugs, radiotherapy and oral candidiasis. Oral Oncol. 2004 Nov;40(10):971-8.[Abstract]
41. Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer. 2006 Jul;14(7):753-62.[Abstract]
42. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238.[Full Text]
43. Wald A, Huang ML, Carrell D, et al. Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture. J Infect Dis. 2003 Nov 1;188(9):1345-51.[Abstract]
44. Lalla RV, Sonis ST, Peterson DE. Management of oral mucositis in patients who have cancer. Dent Clin North Am. 2008 Jan;52(1):61-77, viii.[Abstract][Full Text]
45. Saunders DP, Epstein JB, Elad S, et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer. 2013 Nov;21(11):3191-207.[Abstract]
46. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004 Dec 16;351(25):2590-8.[Abstract][Full Text]
47. Nguyen DT, Shayani S, Palmer J, et al. Palifermin for prevention of oral mucositis in allogeneic hematopoietic stem cell transplantation: a single-institution retrospective evaluation. Support Care Cancer. 2015 Nov;23(11):3141-7.[Abstract]
48. Langner S, Staber P, Schub N, et al. Palifermin reduces incidence and severity of oral mucositis in allogeneic stem-cell transplant recipients. Bone Marrow Transplant. 2008 Aug;42(4):275-9.[Abstract]
49. Riley P, Glenny AM, Worthington HV, et al. Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors. Cochrane Database Syst Rev. 2017 Nov 28;11:CD011990.[Abstract][Full Text]
50. Nicolatou-Galitis O, Bossi P, Orlandi E, et al. The role of benzydamine in prevention and treatment of chemoradiotherapy-induced mucositis. Support Care Cancer. 2021 Oct;29(10):5701-9.[Abstract][Full Text]
51. Lalla RV, Peterson DE. Treatment of mucositis, including new medications. Cancer J. 2006 Sep-Oct;12(5):348-54.[Abstract]
52. Rugo H, Seneviratne L, Beck J, et al. Prevention of everolimus/exemestane (EVE/EXE) stomatitis in postmenopausal (PM) women with hormone receptor-positive (HR+) metastatic breast cancer (MBC) using a dexamethasone-based mouthwash (MW): results of the SWISH trial. 2016 ASCO Annual Meeting;abstract 525. J Clin Oncol. 2016 Oct;34:525.[Full Text]
53. Jiang C, Wang H, Xia C, et al. A randomized, double-blind, placebo-controlled trial of probiotics to reduce the severity of oral mucositis induced by chemoradiotherapy for patients with nasopharyngeal carcinoma. Cancer. 2019 Apr 1;125(7):1081-90.[Abstract][Full Text]
54. Epstein JB, Beaumont JL, Gwede CK, et al. Longitudinal evaluation of the oral mucositis weekly questionnaire-head and neck cancer, a patient-reported outcomes questionnaire. Cancer. 2007 May 1;109(9):1914-22.[Abstract][Full Text]
